Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45


The Endocannabinoid System Alleviates Pain in a Murine Model of Cancer-Induced Bone Pain.

Thompson AL, Grenald S, Ciccone H, BassiriRad N, Niphakis M, Cravatt B, Largent-Milnes TM, Vanderah TW.

J Pharmacol Exp Ther. 2020 Feb 13. pii: jpet.119.262337. doi: 10.1124/jpet.119.262337. [Epub ahead of print]


Glial neuroimmune signaling in opioid reward.

Zhang H, Largent-Milnes TM, Vanderah TW.

Brain Res Bull. 2020 Feb;155:102-111. doi: 10.1016/j.brainresbull.2019.11.012. Epub 2019 Nov 29. Review.


Cdk5-mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain.

Moutal A, Luo S, Largent-Milnes TM, Vanderah TW, Khanna R.

Neurobiol Pain. 2019 Jan-Jul;5. pii: 100022. doi: 10.1016/j.ynpai.2018.07.003. Epub 2018 Jul 26.


Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain.

Chen Z, Doyle TM, Luongo L, Largent-Milnes TM, Giancotti LA, Kolar G, Squillace S, Boccella S, Walker JK, Pendleton A, Spiegel S, Neumann WL, Vanderah TW, Salvemini D.

Proc Natl Acad Sci U S A. 2019 May 21;116(21):10557-10562. doi: 10.1073/pnas.1820466116. Epub 2019 May 8.


Animal Models for the Study of Bone-Derived Pain.

Thompson AL, Largent-Milnes TM, Vanderah TW.

Methods Mol Biol. 2019;1914:391-407. doi: 10.1007/978-1-4939-8997-3_23.


A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.

Hay M, Polt R, Heien ML, Vanderah TW, Largent-Milnes TM, Rodgers K, Falk T, Bartlett MJ, Doyle KP, Konhilas JP.

J Pharmacol Exp Ther. 2019 Apr;369(1):9-25. doi: 10.1124/jpet.118.254854. Epub 2019 Feb 1.


Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery.

Cottier KE, Galloway EA, Calabrese EC, Tome ME, Liktor-Busa E, Kim J, Davis TP, Vanderah TW, Largent-Milnes TM.

eNeuro. 2018 Jul 16;5(4). pii: ENEURO.0116-18.2018. doi: 10.1523/ENEURO.0116-18.2018. eCollection 2018 Jul-Aug.


Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain.

Zhang H, Lund DM, Ciccone HA, Staatz WD, Ibrahim MM, Largent-Milnes TM, Seltzman HH, Spigelman I, Vanderah TW.

Pain. 2018 Sep;159(9):1814-1823. doi: 10.1097/j.pain.0000000000001278.


Continuous remote ischemic conditioning attenuates cognitive and motor deficits from moderate traumatic brain injury.

Pandit V, Khan M, Zakaria ER, Largent-Milnes TM, Hamidi M, O'Keeffe T, Vanderah TW, Joseph B.

J Trauma Acute Care Surg. 2018 Jul;85(1):48-53. doi: 10.1097/TA.0000000000001835.


Chronic morphine exposure potentiates p-glycoprotein trafficking from nuclear reservoirs in cortical rat brain microvessels.

Schaefer CP, Arkwright NB, Jacobs LM, Jarvis CK, Hunn KC, Largent-Milnes TM, Tome ME, Davis TP.

PLoS One. 2018 Feb 7;13(2):e0192340. doi: 10.1371/journal.pone.0192340. eCollection 2018.


17-β-Estradiol induces spreading depression and pain behavior in alert female rats.

Sandweiss AJ, Cottier KE, McIntosh MI, Dussor G, Davis TP, Vanderah TW, Largent-Milnes TM.

Oncotarget. 2017 Dec 9;8(69):114109-114122. doi: 10.18632/oncotarget.23141. eCollection 2017 Dec 26.


A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain.

Edwards KA, Havelin JJ, Mcintosh MI, Ciccone HA, Pangilinan K, Imbert I, Largent-Milnes TM, King T, Vanderah TW, Streicher JM.

J Pain. 2018 Jun;19(6):612-625. doi: 10.1016/j.jpain.2018.01.002. Epub 2018 Jan 31.


Effect of Centruroides antivenom on reversal of methamphetamine-induced hyperkinesis and hyperthermia in rats.

Malekzadeh P, Hu J, Sandweiss AJ, Ameli N, Bierny P, Largent-Milnes TM, Vanderah TW, Shirazi F.

J Pharm Pharmacol (Los Angel). 2017 Apr;5(1). pii: 5. doi: 10.13188/2327-204X.1000020. Epub 2017 Apr 20.


Remote ischemic conditioning preserves cognition and motor coordination in a mouse model of traumatic brain injury.

Sandweiss AJ, Azim A, Ibraheem K, Largent-Milnes TM, Rhee P, Vanderah TW, Joseph B.

J Trauma Acute Care Surg. 2017 Dec;83(6):1074-1081. doi: 10.1097/TA.0000000000001626.


Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.

Grenald SA, Doyle TM, Zhang H, Slosky LM, Chen Z, Largent-Milnes TM, Spiegel S, Vanderah TW, Salvemini D.

Pain. 2017 Sep;158(9):1733-1742. doi: 10.1097/j.pain.0000000000000965.


Blocking CRMP2 SUMOylation reverses neuropathic pain.

Moutal A, Dustrude ET, Largent-Milnes TM, Vanderah TW, Khanna M, Khanna R.

Mol Psychiatry. 2018 Nov;23(11):2119-2121. doi: 10.1038/mp.2017.117. No abstract available.


Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

Sandweiss AJ, McIntosh MI, Moutal A, Davidson-Knapp R, Hu J, Giri AK, Yamamoto T, Hruby VJ, Khanna R, Largent-Milnes TM, Vanderah TW.

Mol Psychiatry. 2018 Aug;23(8):1745-1755. doi: 10.1038/mp.2017.102. Epub 2017 May 9.


Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.

Grenald SA, Young MA, Wang Y, Ossipov MH, Ibrahim MM, Largent-Milnes TM, Vanderah TW.

Neuropharmacology. 2017 Apr;116:59-70. doi: 10.1016/j.neuropharm.2016.12.008. Epub 2016 Dec 20.


Structure-Activity Relationships of [des-Arg7]Dynorphin A Analogues at the κ Opioid Receptor.

Ramos-Colon CN, Lee YS, Remesic M, Hall SM, LaVigne J, Davis P, Sandweiss AJ, McIntosh MI, Hanson J, Largent-Milnes TM, Vanderah TW, Streicher J, Porreca F, Hruby VJ.

J Med Chem. 2016 Nov 23;59(22):10291-10298. Epub 2016 Nov 8.


The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain.

Slosky LM, BassiriRad NM, Symons AM, Thompson M, Doyle T, Forte BL, Staatz WD, Bui L, Neumann WL, Mantyh PW, Salvemini D, Largent-Milnes TM, Vanderah TW.

Pain. 2016 Nov;157(11):2605-2616.


Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain.

Forte BL, Slosky LM, Zhang H, Arnold MR, Staatz WD, Hay M, Largent-Milnes TM, Vanderah TW.

Pain. 2016 Dec;157(12):2709-2721.


Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations.

Deekonda S, Cole J, Sunna S, Rankin D, Largent-Milnes TM, Davis P, BassiriRad NM, Lai J, Vanderah TW, Porecca F, Hruby VJ.

Bioorg Med Chem Lett. 2016 Jan 1;26(1):222-7. doi: 10.1016/j.bmcl.2015.10.081. Epub 2015 Nov 3.


Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.

Giri AK, Apostol CR, Wang Y, Forte BL, Largent-Milnes TM, Davis P, Rankin D, Molnar G, Olson KM, Porreca F, Vanderah TW, Hruby VJ.

J Med Chem. 2015 Nov 12;58(21):8573-83. doi: 10.1021/acs.jmedchem.5b01170. Epub 2015 Oct 30.


Use of Animal Models in Understanding Cancer-induced Bone Pain.

Slosky LM, Largent-Milnes TM, Vanderah TW.

Cancer Growth Metastasis. 2015 Aug 23;8(Suppl 1):47-62. doi: 10.4137/CGM.S21215. eCollection 2015. Review.


Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives.

Deekonda S, Wugalter L, Rankin D, Largent-Milnes TM, Davis P, Wang Y, Bassirirad NM, Lai J, Kulkarni V, Vanderah TW, Porreca F, Hruby VJ.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4683-8. doi: 10.1016/j.bmcl.2015.07.064. Epub 2015 Jul 29.


Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.

Deekonda S, Wugalter L, Kulkarni V, Rankin D, Largent-Milnes TM, Davis P, Bassirirad NM, Lai J, Vanderah TW, Porreca F, Hruby VJ.

Bioorg Med Chem. 2015 Sep 15;23(18):6185-94. doi: 10.1016/j.bmc.2015.07.071. Epub 2015 Aug 4.


Temperature differentially facilitates spontaneous but not evoked glutamate release from cranial visceral primary afferents.

Fawley JA, Hofmann ME, Largent-Milnes TM, Andresen MC.

PLoS One. 2015 May 20;10(5):e0127764. doi: 10.1371/journal.pone.0127764. eCollection 2015.


A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors.

François-Moutal L, Wang Y, Moutal A, Cottier KE, Melemedjian OK, Yang X, Wang Y, Ju W, Largent-Milnes TM, Khanna M, Vanderah TW, Khanna R.

Pain. 2015 Jul;156(7):1247-64. doi: 10.1097/j.pain.0000000000000147.


Animal models for opioid addiction drug discovery.

Grenald SA, Largent-Milnes TM, Vanderah TW.

Expert Opin Drug Discov. 2014 Nov;9(11):1345-54. doi: 10.1517/17460441.2014.966076. Epub 2014 Oct 13. Review.


External QX-314 inhibits evoked cranial primary afferent synaptic transmission independent of TRPV1.

Hofmann ME, Largent-Milnes TM, Fawley JA, Andresen MC.

J Neurophysiol. 2014 Dec 1;112(11):2697-706. doi: 10.1152/jn.00316.2014. Epub 2014 Sep 3.


Capsaicin-responsive corneal afferents do not contain TRPV1 at their central terminals in trigeminal nucleus caudalis in rats.

Hegarty DM, Hermes SM, Largent-Milnes TM, Aicher SA.

J Chem Neuroanat. 2014 Nov;61-62:1-12. doi: 10.1016/j.jchemneu.2014.06.006. Epub 2014 Jul 1.


Physiological temperatures drive glutamate release onto trigeminal superficial dorsal horn neurons.

Largent-Milnes TM, Hegarty DM, Aicher SA, Andresen MC.

J Neurophysiol. 2014 Jun 1;111(11):2222-31. doi: 10.1152/jn.00912.2013. Epub 2014 Mar 5.


Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Nair P, Yamamoto T, Largent-Milnes TM, Cowell S, Kulkarni V, Moye S, Navratilova E, Davis P, Ma SW, Vanderah TW, Lai J, Porreca F, Hruby VJ.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):4975-8. doi: 10.1016/j.bmcl.2013.06.065. Epub 2013 Jul 2.


Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.

Largent-Milnes TM, Brookshire SW, Skinner DP Jr, Hanlon KE, Giuvelis D, Yamamoto T, Davis P, Campos CR, Nair P, Deekonda S, Bilsky EJ, Porreca F, Hruby VJ, Vanderah TW.

J Pharmacol Exp Ther. 2013 Oct;347(1):7-19. doi: 10.1124/jpet.113.205245. Epub 2013 Jul 16.


Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.

Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL 3rd, Chandramouli A, Owusu-Ankomah M, Nikolich-Zugich T, Bloom AP, Jimenez-Andrade JM, King T, Porreca F, Nelson MA, Mantyh PW, Vanderah TW.

J Bone Miner Res. 2013 Jan;28(1):92-107. doi: 10.1002/jbmr.1732.


Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.

Tumati S, Largent-Milnes TM, Keresztes AI, Yamamoto T, Vanderah TW, Roeske WR, Hruby VJ, Varga EV.

Eur J Pharmacol. 2012 Jun 5;684(1-3):64-70.


Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.

Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW, Varga EV.

J Neuroimmunol. 2012 Mar;244(1-2):23-31. doi: 10.1016/j.jneuroim.2011.12.021. Epub 2012 Jan 30.


Activation of descending pain-facilitatory pathways from the rostral ventromedial medulla by cholecystokinin elicits release of prostaglandin-E₂ in the spinal cord.

Marshall TM, Herman DS, Largent-Milnes TM, Badghisi H, Zuber K, Holt SC, Lai J, Porreca F, Vanderah TW.

Pain. 2012 Jan;153(1):86-94. doi: 10.1016/j.pain.2011.09.021. Epub 2011 Oct 24.


Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats.

Tumati S, Roeske WR, Largent-Milnes TM, Vanderah TW, Varga EV.

J Neurosci Methods. 2011 Jul 15;199(1):62-8. doi: 10.1016/j.jneumeth.2011.04.036. Epub 2011 May 6.


Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.

Hanlon KE, Herman DS, Agnes RS, Largent-Milnes TM, Kumarasinghe IR, Ma SW, Guo W, Lee YS, Ossipov MH, Hruby VJ, Lai J, Porreca F, Vanderah TW.

Brain Res. 2011 Jun 13;1395:1-11. doi: 10.1016/j.brainres.2011.04.024. Epub 2011 Apr 20.


Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.

Yamamoto T, Nair P, Largent-Milnes TM, Jacobsen NE, Davis P, Ma SW, Yamamura HI, Vanderah TW, Porreca F, Lai J, Hruby VJ.

J Med Chem. 2011 Apr 14;54(7):2029-38. doi: 10.1021/jm101023r. Epub 2011 Mar 2.


Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.

Largent-Milnes TM, Yamamoto T, Nair P, Moulton JW, Hruby VJ, Lai J, Porreca F, Vanderah TW.

Br J Pharmacol. 2010 Nov;161(5):986-1001. doi: 10.1111/j.1476-5381.2010.00824.x.


Recently patented and promising ORL-1 ligands: where have we been and where are we going?

Largent-Milnes TM, Vanderah TW.

Expert Opin Ther Pat. 2010 Mar;20(3):291-305. doi: 10.1517/13543771003602004. Review.


A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.

Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M, Jimenez-Andrade JM, Mantyh PW, Vanderah TW.

Life Sci. 2010 Apr 24;86(17-18):646-53. doi: 10.1016/j.lfs.2010.02.014. Epub 2010 Feb 20.


Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.

Largent-Milnes TM, Guo W, Wang HY, Burns LH, Vanderah TW.

J Pain. 2008 Aug;9(8):700-13. doi: 10.1016/j.jpain.2008.03.005. Epub 2008 May 12.

Supplemental Content

Loading ...
Support Center